Conference Coverage
Conference Coverage
Some MS treatments may heighten COVID risk
An Italian registry shows worse outcomes with anti-CD20 treatment, but a possible protective effect of interferon and teriflunomide.
Conference Coverage
Evobrutinib may lower nerve damage biomarker levels
A post hoc analysis reports the Bruton’s tyrosine kinase inhibitor evobrutinib lowered neurofilament light chain blood levels in multiple...
Conference Coverage
Common MS treatment wears off more quickly in Black patients
These findings may have implications for the way Black patients with autoimmune diseases are treated in the future.
Conference Coverage
Can supplementary estrogen relieve MS symptoms in menopausal women?
Research suggests lowered hormone levels may worsen the disease.
Conference Coverage
Sun exposure linked to reduced pediatric MS risk
Children should spend at least 30 minutes outdoors in the sun every day, while using adequate sun protection.
Conference Coverage
Erythropoietin falls short of neuroprotection in optic neuritis
“EPO conveyed neither functional nor structural neuroprotection in the visual pathways after optic neuritis as a clinically isolated syndrome.”
Conference Coverage
Disease progression and therapy response vary in MS by ethnicity
African Americans and Hispanics had more severe illness than Caucasians, and there were other differences as well.
Conference Coverage
Newly approved drugs offer new hope in NMOSD
Trio of medications offer relief from relapses, neurologist tells colleagues
Conference Coverage
Infections – especially urinary and kidney – are higher in MS
Among patients with MS, the infection rate was more than quadruple the rate in a control cohort.
Conference Coverage
Anti-CD20s linked to higher COVID-19 severity in MS
Older age and disability are also linked to extra risk, registries find, but not other DMTs.